RESEARCH TRIANGLE PARK, N.C. - February 15, 2001- In alignment with the current contract pharmaceutical organization (CPO) structure established in selected geographic regions, Quintiles Transnational Corp. (Nasdaq: QTRN) today announced the following executive appointment in Latin America:
Alcides Cupido, M.D., vice president, Operations, Latin America. He will be responsible for business management of Quintiles Argentina and Chile and will provide overall strategic direction for clinical development throughout Latin America. This newly created position is aligned with the company's establishment of a CPO structure in geographic regions where Quintiles' development, commercialization and information services are managed within a single organization. Cupido will report to Oppel Greeff, M.D., president, Quintiles, South Africa, India and Latin America.
Cupido has more than 18 years experience in the pharmaceutical industry in Argentina, with positions as head of clinical research at companies including Hoechst (now Aventis). Cupido joined Quintiles in 1995 and assumed responsibilities for implementation and overall business management of company offices in South America. A native of Argentina, Cupido is a board-certified pediatrician with experience in intensive care and private practice.
Dennis Gillings, Ph.D., chairman and chief executive officer of Quintiles Transnational, said: "Taking an integrated approach to providing pharmaceutical services to our regions means we make better use of our resources. But more importantly, we can offer even better service to our customers, making Quintiles the most comprehensive contract clinical and commercial operation in the Southern Hemisphere. "
Quintiles Transnational is the world's leading provider of information, technology and services to bring new medicines to patients faster and improve healthcare. Headquartered near Research Triangle Park, North Carolina, Quintiles employs a global workforce of 18,000 in 39 countries. Quintiles Transnational is a member of the S&P 500 and Fortune 1000. For more information visit the company's Web site at www.quintiles.com.
Information in this press release contains "forward-looking statements" about Quintiles. These statements involve risks and uncertainties that could cause actual results to differ materially, including without limitation, our ability to complete development and commercialization of new products, the cost and timing of bringing new products to market compared with revenues which may be generated by them, market acceptance, our ability to efficiently distribute backlog among therapeutic business units and match demand to resources, actual operating performance, the ability to maintain large client contracts or to enter into new contracts, changes in trends in the pharmaceutical industry, the ability to create data products from data licensed to us and the ability to operate successfully in new lines of business. Additional factors that could cause actual results to differ materially are discussed in the company's recent filings with the Securities and Exchange Commission, including but not limited to its S-3 and S-4 Registration Statements, its Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports, including Form 10-Qs.